Gland Pharma Appoints Srinivas Sadu as CEO

Gland Pharma Limited appoints Srinivas Sadu as the Executive Chairman and Chief Executive Officer (CEO) of the company, and C.S.N. Murthy is appointed as the Independent Director of the company, both effective June 10, 2024.

Yiu Kwan Stanley Lau, Chairman and Non-Executive Independent Director of the company, relinquished his position following the completion of his five-year tenure, with effect from June 9, 2024.

Srinivas Sadu has been associated with Gland Pharma for over twenty-three years and is currently the Managing Director (MD). He started as a company Director in 2000, became the Chief Operating Officer (COO), and held the position for more than thirteen years. He previously worked with SmithKline Beecham as a Product Manager and Natco Pharma as a Senior Manager. His educational background includes a Master of Business Administration (MBA) from the University of Baltimore and a Master of Science in Industrial Pharmacy from Long Island University Brooklyn.

Yiu Kwan Stanley Lau was the Chairman and Independent Director of the company. He serves as a Director on the boards of TaiLai Bioscience and Solasia Pharma. Before this, he served as President of China Biologic Products, Chief Operating Officer of Eddingpharm Investment, and Chief Executive Officer of Amsino Medical Group. Additionally, he has experience working at Baxter (China) Investment and Merck Sharp and Dohme (Asia) Ltd. He graduated from the School of Pharmacy, University of London, with a bachelor’s degree in pharmacy.